Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs.

Author contributions All authors conceived the study, performed the analysis, and have written the manuscript. All authors contributed toward drafting and revising the paper and agree to be accountable for all aspects of the work. Disclosure AR and DPR are consultants for Alfa Wassermann. ER, EC, and MDR declare no conflicts of interest for this work. AG is speaker’s bureau for Janssen, Gilead, Alfa Wassermann, MSD, Zambon, BMS, and AbbVie. PMP was the clinical research director for Alfa Wassermann at the moment of the study. The authors report no other conflicts of interest in this work.